FY2027 Earnings Forecast for DNLI Issued By Zacks Research

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Zacks Research issued their FY2027 earnings estimates for shares of Denali Therapeutics in a report issued on Thursday, March 13th. Zacks Research analyst A. Chakraborty anticipates that the company will post earnings of ($2.25) per share for the year. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08.

A number of other equities analysts have also recently issued reports on the company. Stifel Nicolaus upgraded Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 target price on the stock in a report on Monday, December 16th. JPMorgan Chase & Co. reduced their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. Oppenheimer decreased their target price on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Robert W. Baird started coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $37.20.

Remove Ads

Denali Therapeutics Price Performance

Shares of DNLI traded down $0.18 during trading hours on Monday, hitting $14.64. The stock had a trading volume of 286,260 shares, compared to its average volume of 998,023. The firm has a 50 day simple moving average of $19.91 and a 200-day simple moving average of $23.77. Denali Therapeutics has a 1-year low of $14.01 and a 1-year high of $33.33. The firm has a market capitalization of $2.13 billion, a P/E ratio of -5.31 and a beta of 1.46.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Sterling Capital Management LLC increased its stake in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. Quest Partners LLC purchased a new position in shares of Denali Therapeutics during the third quarter worth about $73,000. GF Fund Management CO. LTD. bought a new position in shares of Denali Therapeutics in the fourth quarter worth approximately $62,000. Point72 Hong Kong Ltd purchased a new stake in Denali Therapeutics in the fourth quarter valued at approximately $65,000. Finally, PNC Financial Services Group Inc. lifted its position in Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after purchasing an additional 885 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Insider Buying and Selling

In other news, Director Vicki L. Sato sold 3,080 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve E. Krognes sold 3,339 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now directly owns 25,757 shares of the company's stock, valued at approximately $536,003.17. This represents a 11.48 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,940 shares of company stock valued at $973,442. Corporate insiders own 7.90% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.